RENOVORX INC

RenovoRx’s next clinical data release, investor talks, and FDA decision could reshape its market valuation—watch for key catalysts amid limited financial disclosure.

RenovoRx’s RenovoCath drug‑delivery system shows promise in Phase 3 TIGeR‑PaC, boosting targeted chemotherapy for pancreatic cancer and driving a new 52‑week high in shares.

Explore RenovoRx’s TAMP platform and Phase III TIGeR-PaC trial in our virtual webinar—discover how targeted micro‑perfusion could change pancreatic cancer treatment.

RenovoRx closes $10 M oversubscribed private placement, boosting funding for its solid‑tumor and pancreatic‑cancer programs and strengthening investor confidence.

RenovoRx, Inc. is a clinical-stage biopharmaceutical company making strides in cancer treatment with its innovative approach to localized therapies for solid tumors and pancreatic cancer, positioning it as a promising player in the healthcare sector.

RenovoRx Inc.’s financial performance is marked by a 28% revenue surge, but also persistent losses and a struggle to meet revenue expectations, leaving investors and analysts to weigh the company’s potential for growth and profitability.